Table 5.
Prognostic factors reported by literature.
| Author/Year | Univariate | Multivariate | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| OS | Overall Effect Size | 95% CI of Overall Effect | DFS | Overall Effect Size | 95% CI of Overall Effect | OS | Overall Effect Size | 95% CI of Overall Effect | DFS | Overall Effect Size | 95% CI of Overall Effect | |
| Min et al./2008 | Poorly/Mucinous primary tumor grade | / | / | / | / | / | Poorly/Mucinous primary tumor grade | HR = 2.844 | 1.037–7.797 | / | / | / |
| PALNM resection | / | / | ||||||||||
| Location i-PALNM | / | / | ||||||||||
| Choi et al./2010 | PALNM ≥ 3 | / | / | PALNM ≥ 3 | / | / | None | n/a | n/a | None | n/a | n/a |
| Gagnière et al./2015 | Primary TNM Stage III | / | / | None | n/a | n/a | / | / | / | / | / | / |
| Song et al./2016 | Primary TNM Stage IV | / | / | Primary TNM Stage IV | / | / | / | / | / | / | / | / |
| PALNM ≥ 4 | / | / | ||||||||||
| Ogura et al./2017 | None | n/a | n/a | Total LNM ≥ 7 | / | / | / | / | / | / | / | / |
| Regional LNM ≥ 4 | / | / | ||||||||||
| Bae et al./2018 | PALNM > 7 | / | / | PALNM > 7 | / | / | PALNM > 7 | HR = 3.291 | 1.309–8.275 | PALNM > 7 | HR = 2.484 | 0.993–6.211 |
| Preoperative CEA > 5 | / | / | Preoperative CEA > 5 | / | / | Preoperative CEA > 5 | HR = 1.953 | 0.940–4.057 | ||||
| Yamamoto et al./2019 | / | / | / | / | / | / | / | / | / | / | / | / |
| Kim et al./2020 | DFI < 24 mo | HR = 0.457 | 0.218–0.958 | / | / | / | DFI < 24 mo | HR = 0.321 | 0.125–0.821 | / | / | / |
| Primary pN | HR = 4.296 | 1.554–11.875 | / | / | / | Primary pN | HR = 4.062 | 1.365–12.090 | / | / | / | |
| PALNM resection | HR = 0.347 | 0.160–0.752 | / | / | / | PALNM resection | HR = 0.379 | 0.151–0.955 | / | / | / | |
| Sakamoto et al./2020 | Poorly/Mucinous primary tumor grade | HR = 4.21 | 1.67–10.6 | pM1 b/c | HR = 3.59 | 1.15–11.21 | Poorly/Mucinous primary tumor grade | HR = 7.18 | 2.21–23.4 | pM1 b/c | HR = 2.49 | 1.05–5.90 |
| pM1 b/c | HR = 3.01 | 1.19–7.65 | pM1 b/c | HR = 5.15 | 1.52–17.5 | |||||||
| PALNM ≥ 4 | HR = 2.81 | 1.07–7.39 | ||||||||||
OS = Overall survival; DFS = Disease-free survival; PALNM = Para-aortic lymph node metastases; DFI = Disease-free interval; n/a = not applicable.